D68.61Antiphospholipid syndrome

D68.61 is the ICD-10-CM diagnosis code for Antiphospholipid syndrome. It belongs to category D68 (other coagulation defects), block D65-D69 (coagulation defects, purpura and other hemorrhagic conditions) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D68.6 (other thrombophilia), D68.61 is specifically for Antiphospholipid syndrome. Related codes cover lupus anticoagulant syndrome (D68.62) and other thrombophilia (D68.69).

Don't report D68.61 together with the conditions in its Excludes1 note: anti-phospholipid antibody, finding without diagnosis (R76.0).

The conditions in its Excludes2 note aren't part of D68.61, but may be coded alongside it if the patient has both: anti-phospholipid antibody with hemorrhagic disorder (D68.312) and lupus anticoagulant syndrome (D68.62).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 289.81 (primary hypercoagulable state).